Evaluation of pregnancy-specific beta 1-glycoprotein in patients with non-seminomatous testicular germ cell tumors.

Abstract

Serum SP-1 levels were measured serially in 94 patients with non-seminomatous germ cell tumors to evaluate its clinical significance as a tumor marker. In 12 out of 80 patients (15%) with active tumors serum SP-1 was found to be elevated, whereas serum HCG and AFP in the same sample were raised in 53 and 45% respectively. Elevation of serum SP-1 levels was always associated with raised HCG levels, and with AFP in 7 patients. During chemotherapy, serum SP-1 and HCG disappeared when a complete remission was obtained. In contrast to HCG, serum SP-1 failed to detect tumor progression in two patients. Serum HCG and AFP are superior as tumor markers to serum SP-1.

• Authors: H W de Bruijn, A J Suurmeijer, D T Sleijfer, H S Koops, T Ockhuizen, P H Willemse, J Marrink
• Journal: European journal of cancer & clinical oncology (Eur J Cancer Clin Oncol) Vol. 18 Issue 10 Pg. 911-6 (Oct 1982) ISSN: 0277-5379 [Print] England
• PMID: 6186495 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Chorionic Gonadotropin
• Pregnancy Proteins
• Pregnancy-Specific beta 1-Glycoproteins
• alpha-Fetoproteins

Topics

• Chorionic Gonadotropin (blood)
• Follow-Up Studies
• Half-Life
• Humans
• Male
• Neoplasm Staging
• Neoplasms, Germ Cell and Embryonal (blood, drug therapy)
• Pregnancy Proteins (analysis)
• Pregnancy-Specific beta 1-Glycoproteins (analysis)
• Testicular Neoplasms (blood, drug therapy)
• alpha-Fetoproteins (analysis)